{"id":22945,"date":"2022-04-07T15:10:55","date_gmt":"2022-04-07T14:10:55","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=22945"},"modified":"2022-04-07T15:10:59","modified_gmt":"2022-04-07T14:10:59","slug":"rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/","title":{"rendered":"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020"},"content":{"rendered":"\n<p>Article publi\u00e9 sur <a href=\"https:\/\/www.santepubliquefrance.fr\/les-actualites\/2022\/infections-a-campylobacter-donnees-epidemiologiques-2020\" target=\"_blank\" rel=\"noreferrer noopener\">Sant\u00e9 publique France <\/a>le 06 avril 2022<\/p>\n\n\n\n<p>Sant\u00e9 publique France publie les donn\u00e9es de surveillance des infections \u00e0 Campylobacter en France en 2020, dont les tendances observ\u00e9es ces derni\u00e8res ann\u00e9es se confirment.<\/p>\n\n\n\n<p>L\u2019infection \u00e0\u00a0<a href=\"https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-infectieuses-d-origine-alimentaire\/campylobacter\" target=\"_blank\" rel=\"noreferrer noopener\">Campylobacter<\/a>\u00a0est l\u2019une des causes les plus fr\u00e9quentes de gastro-ent\u00e9rites bact\u00e9riennes dans les pays d\u00e9velopp\u00e9s. Une grande partie des infections \u00e0 Campylobacter restent asymptomatiques. Pour les cas symptomatiques, les sympt\u00f4mes g\u00e9n\u00e9ralement observ\u00e9s sont ceux d\u2019une\u00a0<a href=\"https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-infectieuses-d-origine-alimentaire\/gastro-enterites-aigues\" target=\"_blank\" rel=\"noreferrer noopener\">gastro-ent\u00e9rite aigu\u00eb<\/a>\u00a0le plus souvent b\u00e9nigne et spontan\u00e9ment gu\u00e9rie en moins d\u2019une semaine.<\/p>\n\n\n\n<p>Les complications associ\u00e9es \u00e0 une infection \u00e0 Campylobacter sont rares, de m\u00eame que les d\u00e9c\u00e8s (&lt;0,1 %), et surviennent surtout chez les personnes fragiles (personnes \u00e2g\u00e9es, patients immunod\u00e9prim\u00e9s). \u00a0<\/p>\n\n\n\n<p>Chaque ann\u00e9e, Sant\u00e9 publique France publie sur son site internet un bilan complet des donn\u00e9es de surveillance des infections \u00e0 Campylobacter. Cette surveillance repose sur le\u00a0<a href=\"http:\/\/www.cnrch.fr\/\" target=\"_blank\" rel=\"noreferrer noopener\">Centre national de r\u00e9f\u00e9rence<\/a>\u00a0(CNR) des Campylobacters et H\u00e9licobacters et la d\u00e9claration obligatoire des\u00a0<a href=\"https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-infectieuses-d-origine-alimentaire\/toxi-infections-alimentaires-collectives\" target=\"_blank\" rel=\"noreferrer noopener\">toxi-infections alimentaires collectives<\/a>\u00a0(TIAC).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Campylobacter : chiffres cl\u00e9s 2020<\/h2>\n\n\n\n<p>En 2020, la surveillance des infections \u00e0 Campylobacter a confirm\u00e9 les tendances \u00e9pid\u00e9miologiques et biologiques d\u00e9j\u00e0 observ\u00e9es ces derni\u00e8res ann\u00e9es. Plus particuli\u00e8rement, les donn\u00e9es montrent :<\/p>\n\n\n\n<ul><li>une pr\u00e9dominance de l\u2019esp\u00e8ce\u00a0<em>C. jejuni<\/em>\u00a0;<\/li><li>un nombre de cas et une incidence plus \u00e9lev\u00e9s chez les enfants ;<\/li><li>une pr\u00e9dominance des infections chez les hommes, sauf chez les personnes \u00e2g\u00e9es de 30 \u00e0 39 ans ;<\/li><li>un pic saisonnier pendant la p\u00e9riode estivale ;<\/li><li>une r\u00e9sistance \u00e9lev\u00e9e aux fluoroquinolones et aux t\u00e9tracyclines, rest\u00e9e stable ces derni\u00e8res ann\u00e9es ;<\/li><li>pas d\u2019augmentation notable des taux de r\u00e9sistances des six antibiotiques test\u00e9s en routine ;<\/li><li>une consommation de produits de volaille en tant que premier aliment (incrimin\u00e9 ou suspect\u00e9) identifi\u00e9 comme source de contamination dans les \u00e9pisodes de toxi-infections alimentaires collectives.<\/li><\/ul>\n\n\n\n<p>Le nombre de souches de Campylobacter rapport\u00e9 par le CNR est en augmentation depuis 2013, ann\u00e9e de la mise en place de la saisie directe des donn\u00e9es en ligne par les laboratoires. Cette augmentation doit \u00eatre consid\u00e9r\u00e9e dans le cadre des sp\u00e9cificit\u00e9s du syst\u00e8me de surveillance car plusieurs facteurs, comme une augmentation de l\u2019activit\u00e9 des laboratoires du r\u00e9seau ou des prescriptions de coprocultures, pourraient provoquer une augmentation du nombre d\u2019isolements et de la notification au cours du temps. La mise en place de PCR multiplex dans de nombreux laboratoires a aussi facilit\u00e9 la d\u00e9tection de Campylobacter dans les pr\u00e9l\u00e8vements de selles.<\/p>\n\n\n\n<p>Le contexte sanitaire li\u00e9 \u00e0 la\u00a0<a href=\"https:\/\/www.santepubliquefrance.fr\/dossiers\/coronavirus-covid-19\" target=\"_blank\" rel=\"noreferrer noopener\">pand\u00e9mie de COVID-19<\/a>\u00a0ne semble pas avoir eu d\u2019impact sur les donn\u00e9es de surveillance. Une diminution du nombre de souches par rapport aux ann\u00e9es pr\u00e9c\u00e9dentes \u00e9tait observ\u00e9e uniquement en mars-avril 2020, correspondant \u00e0 la p\u00e9riode du premier confinement. Cette diminution semble refl\u00e9ter un moindre recours aux soins (consultation m\u00e9dicale, analyses biologiques) lors de cette p\u00e9riode, mais pourrait aussi indiquer une diminution de l\u2019incidence li\u00e9e aux restrictions sanitaires.<\/p>\n\n\n\n<p>T\u00e9l\u00e9chargez le rapport <a href=\"https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-infectieuses-d-origine-alimentaire\/campylobacter\/documents\/bulletin-national\/bilan-de-la-surveillance-des-infections-a-campylobacter-en-france-en-2020\" target=\"_blank\" rel=\"noreferrer noopener\">sur cette page<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article publi\u00e9 sur Sant\u00e9 publique France le 06 avril 2022 Sant\u00e9 publique France publie les donn\u00e9es de surveillance des infections \u00e0 Campylobacter en France en 2020, dont les tendances observ\u00e9es ces derni\u00e8res ann\u00e9es se confirment. L\u2019infection \u00e0\u00a0Campylobacter\u00a0est l\u2019une des causes les plus fr\u00e9quentes de gastro-ent\u00e9rites bact\u00e9riennes dans les pays d\u00e9velopp\u00e9s. Une grande partie des infections [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":22961,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[37],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-07T14:10:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-07T14:10:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"808\" \/>\n\t<meta property=\"og:image:height\" content=\"388\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020\",\"datePublished\":\"2022-04-07T14:10:55+00:00\",\"dateModified\":\"2022-04-07T14:10:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/\"},\"wordCount\":537,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg\",\"articleSection\":[\"Bilans, rapports et recommandations\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/\",\"name\":\"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg\",\"datePublished\":\"2022-04-07T14:10:55+00:00\",\"dateModified\":\"2022-04-07T14:10:59+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg\",\"width\":808,\"height\":388,\"caption\":\"Cr\u00e9dit : Sant\u00e9 publique France\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bilans, rapports et recommandations\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/","og_locale":"fr_FR","og_type":"article","og_title":"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-04-07T14:10:55+00:00","article_modified_time":"2022-04-07T14:10:59+00:00","og_image":[{"width":808,"height":388,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020","datePublished":"2022-04-07T14:10:55+00:00","dateModified":"2022-04-07T14:10:59+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/"},"wordCount":537,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg","articleSection":["Bilans, rapports et recommandations"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/","name":"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020 - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg","datePublished":"2022-04-07T14:10:55+00:00","dateModified":"2022-04-07T14:10:59+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Campylobacter.jpg","width":808,"height":388,"caption":"Cr\u00e9dit : Sant\u00e9 publique France"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/rapport-de-sante-publique-france-infections-a-campylobacter-donnees-epidemiologiques-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Bilans, rapports et recommandations","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/bilans-rapports-et-recommandations\/"},{"@type":"ListItem","position":4,"name":"Rapport de Sant\u00e9 publique France : Infections \u00e0 Campylobacter : donn\u00e9es \u00e9pid\u00e9miologiques 2020"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-17 23:39:25","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/22945"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=22945"}],"version-history":[{"count":11,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/22945\/revisions"}],"predecessor-version":[{"id":22971,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/22945\/revisions\/22971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/22961"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=22945"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=22945"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=22945"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}